Results 91 to 100 of about 18,617,874 (263)
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source
Nanomaterials offer dual applications in allergy management. For diagnosis, nanomaterials enhance analytical sensitivity and improve detection in specific IgE and functional assays such as the basophil activation test (BAT). For allergen‐specific immunotherapy, nanomaterials enable allergen masking and controlled release, and effectively modulate the ...
Madiha Habib +8 more
wiley +1 more source
Open-Label Placebos as Adjunct for the Preventive Treatment of Migraine
Importance Placebo effects contribute substantially to the therapeutic success of many treatments, particularly in pain-related conditions. Open-label placebos (OLPs) offer an ethically acceptable approach to harness this potential without deception ...
Kleine-Borgmann, Julian +6 more
openaire +5 more sources
Safety Profile of Opicapone in the Management of Parkinson’s Disease
Background: Opicapone is a catechol O-methyltransferase (COMT) inhibitor indicated for use as adjunct to levodopa therapy in patients with Parkinson’s disease (PD) and motor fluctuations.
Andrew Lees +6 more
doaj +1 more source
Results show significant improvements for the open-label placebo group but not for the control group. * p < 0.05, (*) p = 0.06.
Benjamin Berstecher (4919128) +2 more
core +1 more source
OAF Blocks SIAH1‐Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD
This study shows OAF directly binds to SCPX and inhibits its interaction with the E3 ligase SIAH1, thereby protecting SCPX from ubiquitin‐dependent degradation and stabilizing its levels. This OAF‐SCPX axis represents a novel pathway in lipid homeostasis, highlighting OAF as a promising therapeutic candidate for MASLD.
Zongxi Li +11 more
wiley +1 more source
Die vorliegende Studie untersuchte die Auswirkung der motorischen Komponente bei einer Open-Label-Placebo Intervention zur Reduktion des Unbehagens (Valenz) und der subjektiven Erregung (Arousal) sowie kardiovaskulärer Parameter, beim Betrachten ...
Keßler, Jarmila Magdalena
core
Open-label placebos, rituals, and well-being
The experiment aims are to test: a) whether open-label placebo (OLP) capsules can improve self-reported measures of wellbeing in a healthy population, and b) whether adding ritualistic components to the OLP capsules use can further enhance the OLP effect.
Marco Valerio
core +1 more source
In colitis patients and mice, reduced Lactobacillus abundance is observed. Experimental studies show that L. plantarum A736 metabolizes dietary tryptophan into indole‐3‐lactic acid (ILA), while both L. plantarum A736 and ILA impact ChAT‐expressing enteric neurons and acetylcholine levels, thereby regulating intestinal immune responses and alleviating ...
Bing Xia +15 more
wiley +1 more source
The therapeutic oxymoron: exploring the mechanisms of open-label placebo
Placebos have emancipated themselves from earlier, often unethical or merely research- based practices, toward an open and thereby ethical administration. Despite a plethora of efficacy studies and nearly two decades of empirical research on open-label placebos (OLPs), little to nothing is known about the circumstances under which they realize their ...
openaire +1 more source

